China Approves Emergency Use of COVID Vaccine for Children Aged 3 to 17

Phase 2 Clinical Trial Results of CNBG under Sinopharm Show 96.1% Antibody Generation with No Observed Side Effects
China First to Approve Vaccine Use for Children... Delta Variant-Specific Vaccine Also in Development

[Asia Economy Beijing=Special Correspondent Jo Young-shin] Chinese health authorities have approved the emergency use of COVID-19 vaccines for children aged 3 to 17.

The state-run Global Times reported that China National Biotec Group (CNBG), a subsidiary of the Chinese state-owned pharmaceutical company Sinopharm, has received emergency approval for the use of its COVID-19 vaccine in children aged 3 to 17. This marks the first time China has approved COVID-19 vaccination for children in this age group.

Photo by Global Times capture

CNBG explained that Phase 1 and Phase 2 clinical trial results showed high neutralizing antibody levels in this age group.

CNBG added that 96.1% of children who received two doses of the vaccine developed antibodies, and the results were not significantly different from those in adults. They also noted that no serious adverse reactions were observed after vaccination.

The Global Times reported that the clinical trials were primarily conducted by the Henan Provincial Center for Disease Control and Prevention in China, and considering safety issues and production capacity, plans will be made for COVID-19 vaccination for children going forward.

Meanwhile, CNBG stated that it is currently developing a vaccine specifically targeting the Delta variant at its Wuhan research institute.

This content was produced with the assistance of AI translation services.